Salvadora persica mediated synthesis of silver nanoparticles and their antimicrobial efficacy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Metal Nanoparticles*/chemistry ; Silver*/chemistry ; Silver*/metabolism; Anti-Infective Agents/*pharmacology ; Plant Extracts/*chemistry ; Salvadoraceae/*chemistry; Anti-Infective Agents/chemistry ; Dose-Response Relationship, Drug ; Microbial Sensitivity Tests ; Nanotechnology
    • Abstract:
      Silver nanoparticles (AgNPs) exhibit strong antimicrobial properties against many pathogens. Traditionally employed chemical methods for AgNPs synthesis are toxic for the environment. Here, we report a quicker, simpler, and environmentally benign process to synthesize AgNPs by using an aqueous 'root extract' of Salvadora persica (Sp) plant as a reducing agent. The synthesized Salvadora persica nano particles (SpNPs) showed significantly higher antimicrobial efficacy compared to earlier reported studies. We characterized SpNPs using UV-Vis spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), Transmission Electron Microscopy (TEM), Field Emission Scanning Electron Microscopy (FE-SEM), Dynamic Light Scattering (DLS) and X-ray powder diffraction (P-XRD). UV-Vis spectrum showed the highest absorbance at 420 nm. FTIR analysis depicts presence of bond stretching including OH- (3300 cm -1 ), C=N- (2100 cm -1 ) and NH- (1630 cm -1 ) which are attributed in the involvement of phenolics, proteins or nitrogenous compounds in reduction and stabilization of AgNPs. TEM, FE-SEM and DLS analysis revealed the spherical and rod nature of SpNPs and an average size of particles as 37.5 nm. XRD analysis showed the presence of the cubic structure of Ag which confirmed the synthesis of silver nanoparticles. To demonstrate antimicrobial efficacy, we evaluated SpNPs antimicrobial activity against two bacterial pathogens (Escherichia coli (ATCC 11229) and Staphylococcus epidermidis (ATCC 12228)). SpNPs showed a significantly high inhibition for both pathogens and minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were found to be 0.39 µg/mL and 0.78 µg/mL for E. coli while 0.19 µg/mL and 0.39 µg/mL for S. epidermidis respectively. Further, Syto 16 staining of bacterial cells provided a supplemental confirmation of the antimicrobial efficacy as the bacterial cells treated with SpNPs stop to fluoresce compared to the untreated bacterial cells. Our highly potent SpNPs will likely have a great potential for many antimicrobial applications including wound healing, water purification, air filtering and other biomedical applications.
    • References:
      BMC Microbiol. 2015 Feb 18;15:36. (PMID: 25881030)
      Appl Microbiol Biotechnol. 2015 Dec;99(23):9923-34. (PMID: 26392135)
      Pharmacogn Rev. 2010 Jul;4(8):209-14. (PMID: 22228963)
      Int J Mol Sci. 2019 Jan 21;20(2):. (PMID: 30669621)
      Res Pharm Sci. 2014 Nov-Dec;9(6):385-406. (PMID: 26339255)
      Enzyme Microb Technol. 2017 Feb;97:21-26. (PMID: 28010769)
      Artif Cells Nanomed Biotechnol. 2017 Mar;45(2):372-379. (PMID: 27023851)
      PeerJ. 2016 Oct 19;4:e2589. (PMID: 27781173)
      Nanomedicine. 2016 Apr;12(3):789-799. (PMID: 26724539)
      Nat Nanotechnol. 2018 Jan;13(1):65-71. (PMID: 29203912)
      J Adv Res. 2016 Jan;7(1):17-28. (PMID: 26843966)
      IET Nanobiotechnol. 2015 Oct;9(5):314-23. (PMID: 26435286)
      J Med Microbiol. 2005 Jan;54(Pt 1):77-81. (PMID: 15591259)
      Appl Microbiol Biotechnol. 2017 Jan;101(1):79-92. (PMID: 27915376)
      J Ethnopharmacol. 2018 Mar 1;213:409-444. (PMID: 29196134)
      Front Microbiol. 2017 Feb 15;8:167. (PMID: 28261161)
      RSC Adv. 2019 Jan 21;9(5):2673-2702. (PMID: 35520490)
      Biomolecules. 2020 Aug 25;10(9):. (PMID: 32854282)
      Biomacromolecules. 2020 May 11;21(5):1802-1811. (PMID: 31967794)
      Nanoscale Res Lett. 2016 Dec;11(1):80. (PMID: 26858162)
      Saudi Med J. 2015 May;36(5):530-43. (PMID: 25935172)
      Medicina (Kaunas). 2019 Aug 05;55(8):. (PMID: 31387257)
      Cell Mol Biol (Noisy-le-grand). 2016 Aug 29;62(9):46-50. (PMID: 27585261)
      ACS Appl Mater Interfaces. 2017 Jul 19;9(28):24190-24197. (PMID: 28644011)
      J Antimicrob Chemother. 2020 Dec 1;75(12):3665-3674. (PMID: 32865203)
      J Clin Microbiol. 1980 Oct;12(4):550-3. (PMID: 6999022)
      Evid Based Complement Alternat Med. 2016;2016:7083964. (PMID: 26904146)
      F1000Res. 2019 Jan 30;8:. (PMID: 30755795)
      Nanoscale Res Lett. 2015 Dec;10(1):987. (PMID: 26138452)
      Iran J Pharm Res. 2019 Fall;18(4):2101-2110. (PMID: 32184873)
      IEEE Trans Nanobioscience. 2016 Jul;15(5):433-442. (PMID: 27164598)
      Chem Biol Interact. 2019 Oct 1;312:108814. (PMID: 31509734)
      Molecules. 2016 Nov 06;21(11):. (PMID: 27827968)
      J Pharm Bioallied Sci. 2011 Jan;3(1):113-7. (PMID: 21430961)
      Prep Biochem Biotechnol. 2018;48(7):646-652. (PMID: 29958093)
      Environ Monit Assess. 2017 Jul;189(7):349. (PMID: 28646435)
      Microb Pathog. 2018 Jan;114:180-192. (PMID: 29196174)
    • Accession Number:
      0 (Anti-Infective Agents)
      0 (Plant Extracts)
      3M4G523W1G (Silver)
    • Publication Date:
      Date Created: 20210317 Date Completed: 20211215 Latest Revision: 20231111
    • Publication Date:
      20240829
    • Accession Number:
      PMC7966387
    • Accession Number:
      10.1038/s41598-021-85584-w
    • Accession Number:
      33727607